Publications (1)0 Total impact
ABSTRACT: Aims/hypothesisGrowth hormone has been used experimentally in two studies to treat individuals with type 2 diabetes, with both reporting
beneficial effects on glucose metabolism. However, concerns over potential diabetogenic actions of growth hormone complicate
its anticipated use to treat type 2 diabetes. Thus, an animal model of type 2 diabetes could help evaluate the effects of
growth hormone for treating this condition.
MethodsMale C57BL/6J mice were placed on a high-fat diet to induce obesity and type 2 diabetes. Starting at 16 weeks of age, mice
were treated once daily for six weeks with one of four different doses of growth hormone. Body weight, body composition, fasting
blood glucose, insulin, glucose tolerance, liver triacylglycerol, tissue weights and blood chemistries were determined.
ResultsBody composition measurements revealed a dose-dependent decrease in fat and an increase in lean mass. Analysis of fat loss
by depot revealed that subcutaneous and mesenteric fat was the most sensitive to growth hormone treatment. In addition, growth
hormone treatment resulted in improvement in glucose metabolism, with the highest dose normalising glucose, glucose tolerance
and liver triacylglycerol. In contrast, insulin levels were not altered by the treatment, nor did organ weights change. However,
fasting plasma leptin and resistin were significantly decreased after growth hormone treatment.
Conclusions/interpretationGrowth hormone therapy improves glucose metabolism in this mouse model of obesity and type 2 diabetes, providing a means to
explore the molecular mechanism(s) of this treatment.